两种阿德福韦酯治疗HBeAg阳性慢性乙型肝炎的临床研究  

Clinical study of effects of two different kinds of adefovir dipivoxil on HBeAg-positive chronic hepatitis B

作　　者：黄平[1] 杨高雄[1] 黄江秀 林龙[1] 黄存敏 

机构地区：[1]廉江市人民医院感染内科,广东廉江524400

出　　处：《华夏医学》2016年第4期59-61,共3页Acta Medicinae Sinica

摘　　要：目的:观察比较国产阿德福韦酯(利福之)与进口阿德福韦酯(贺维力)治疗HBeAg阳性慢性乙型肝炎48周的疗效。方法:80例患者按就诊顺序分别纳入治疗组(40例)和对照组(40例)。治疗组每天口服利福之10 mg,对照组每天口服贺维力10 mg,疗程均为48周。治疗前和治疗后12,24,36,48周分别检测血清HBV DNA定量、血清HBV标志物、ALT水平。比较两组48周时HBV DNA水平、HBV DNA阴转率、HBeAg血清转换率、ALT复常率。结果:两组患者在治疗后第12,24,36,48周的HBV DNA水平、HBV DNA阴转率、HBeAg血清转换率、ALT复常率均差异无统计学意义。结论:国产与进口阿德福韦酯治疗HBeAg阳性慢性乙型肝炎,利福之与贺维力均能有效改善肝功能,抑制HBV DNA及有较好的安全性。Objective： To compare the efficacy and safety between two kinds of adefovir dipivoxil （domestic lifu- zhi and imported hepsera） on the treatment of HBeAg-positive chronic hepatitis B （CHB） for 48 weeks. Methods： 80 patients with HBeAg-positive CHB were included into lifuzhi group （n = 40, 10rag qd） and hepsera group （n =40,10mg qd） in terms of registration order. The respective serum HBV DNA quantifi- cation, t-IBV markers and ALT level before the treatment and 12, 24, 36 and 48 weeks after the treatment were de- termined. And level and negative conversion rate of HBV DNA, seroconversion rate of HbeAg, normalization rate of ALT of both groups at 48th week were compared. Results： There were no significant differences of the nor- malization rate of ALT, HBV DNA level, and seroconversion rate of I＇-IBeAg between both groups （P 〉 0.05）. Conclusion： Two kinds of adefovir dipivoxil （Lifuzlhi and Hepsera） are effective and safe in improving liver func- tions and suppressing HBV replication.

关 键 词：慢性乙型肝炎 HBEAG阳性 阿德福韦酯 疗效 

分 类 号：R512.62[医药卫生—内科学]